LB Pharmaceuticals Inc: 5%+ holders

As of November 7, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of LB Pharmaceuticals Inc. The largest reported stake is Deep Track Capital, LP's, at 11.7%. 20 filings are on record since September 18, 2025 (Schedule 13D/A, February 10, 2026).

Pontifax Management 4 G.P. (2015) Ltd. also filed stake reports on 3 other companies ↓

Sell to companies like LB Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-13 · Reporting person: Jpmorgan Chase & Co. · Sole voting: 1,334,100 · Shared voting: 7 · Sole dispositive: 1,401,783 · Shared dispositive: 7 · SCHEDULE 13G/A, 2026-10-13
• Filing 2026-08-14 · Reporting person: TCG Crossover GP II, LLC · Sole voting: 0 · Shared voting: 1,447,310 · Sole dispositive: 0 · Shared dispositive: 1,447,310 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-07-29 · Reporting person: BlackRock, Inc. · Sole voting: 1,771,160 · Shared voting: 0 · Sole dispositive: 1,796,543 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-29
• Filed 2026-07-16 · Holder: Jpmorgan Chase & Co · Percent: 5.2% · SCHEDULE 13G
• Filed 2026-05-15 · Holder: TCG Crossover GP II, LLC · Percent: 6.4% · SCHEDULE 13G/A

LB Pharmaceuticals Inc has 20 Schedule 13D or 13G filings on record since 2025-09-18. 8 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind LB Pharmaceuticals Inc and the warning signs.

See LB Pharmaceuticals Inc's free Snapshot Watch LB Pharmaceuticals Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on LB Pharmaceuticals Inc and the records around it.

LB Pharmaceuticals Inc elsewhere on the record

• Leadership changes Sep 2026
• Who owns it

Companies that share a holder

• Pontifax Management 4 G.P. (2015) Ltd. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), Keros Therapeutics, Inc. (Oct 2025), Climb Bio, Inc. (Sep 2025)
• Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
• Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)

Want the whole picture on LB Pharmaceuticals Inc?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on LB Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on LB Pharmaceuticals Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   27 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies LB Pharmaceuticals Inc by CUSIP 50180M108 and gives its principal executive office as One Pennsylvania Plaza, Suite 1025, New York, NY 10119 (SCHEDULE 13G/A, 2026-10-13).

Purpose of Transaction (Item 4)

Deep Track Capital, LP

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On February 4, 2026, the Issuer entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Investors") pursuant to which the Issuer, in a private placement (the "Private Placement"), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the "Shares") of the Issuer's Common Stock and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,417,107 shares of Common Stock (such shares issuable upon exercise of the Pre-Funded Warrants, the "Warrant Shares", and together with the Shares and the Pre-Funded Warrants, the "Securities"). Each Share was offered and sold at a purchase price of $21.17 before deducting underwriting discounts and commissions and each Pre-Funded Warrant was offered and sold at a purchase price of $21.1699, which is equal to the purchase price per Share less the $0.0001 exercise price of each Pre-Funded Warrant, before deducting underwriting discounts and commissions. Each of Deep Track Biotechnology Master Fund, Ltd ("DTBMF") and Deep Track Special Opportunities Fund, LP ("DTSOF") purchased 378,444 and 93,925 Pre-Funded Warrants, respectively, in the Private Placement. The Private Placement closed on February 6, 2026. Each Pre-Funded Warrant has an initial exercise price per share of $0.0001, subject to certain adjustments. The Pre-Funded Warrants are exercisable immediately and may be exercised …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-02-10; the filing has the rest

Pontifax Management 4 G.P. (2015) Ltd.

The Reporting Persons acquired the securities reported herein for investment purposes, subject to the following: The Reporting Persons intend to review on a continuing basis the investments in the Issuer by the Reporting Persons. The Reporting Persons may engage in discussions with management, the board of directors of the Issuer (the "Board"), other shareholders of the Issuer and other relevant parties concerning the Reporting Persons' investment in the Issuer's securities. Depending on various factors, including, without limitation, the price and availability of the Issuer's securities, subsequent developments affecting the Issuer, the Issuer's business and the Issuer's prospects, other investment and business opportunities available to such Reporting Persons, general industry and economic conditions, the securities markets in general, tax considerations and other factors deemed relevant by such Reporting Persons, the Reporting Persons may seek to sell or otherwise dispose some or all of the Issuer's securities or any derivatives thereof (which may include distributing some or all of such securities to such Reporting Person's respective partners or beneficiaries, as applicable) from time to time, and/or may seek to acquire additional securities of the Issuer or any derivatives thereof (which may include rights or securities exercisable or convertible into securities of the Issuer) from time to time, in each case, in open market or private transactions, block sales or …The first part of Item 4 of the SCHEDULE 13D filed 2025-09-25; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns LB Pharmaceuticals Inc

Who owns LB Pharmaceuticals Inc?

On this page, 8 holders' latest ownership filings report 5% or more of LB Pharmaceuticals Inc: Deep Track Capital, LP (11.7%, Schedule 13D/A, filed 2026-02-10), RA Capital Management, L.P. (8.7%, Schedule 13G/A, filed 2026-02-17), Commodore Capital LP (6.8%, Schedule 13G/A, filed 2026-05-15), Pontifax Management 4 G.P. (2015) Ltd. (6.3%, Schedule 13D, filed 2025-09-25) and BlackRock, Inc. (6.3%, Schedule 13G/A, filed 2026-07-29); 3 more are listed above.

Who are the largest shareholders of LB Pharmaceuticals Inc?

By the share each holder's latest filing reports, the largest holders of LB Pharmaceuticals Inc on this page are Deep Track Capital, LP (11.7%), RA Capital Management, L.P. (8.7%) and Commodore Capital LP (6.8%).

When did Deep Track Capital, LP buy into LB Pharmaceuticals Inc?

The filings give report dates, not purchase dates. The earliest filing from Deep Track Capital, LP on this page is the Schedule 13D, filed 2025-09-19, reporting 14.9%; its latest, Schedule 13D/A filed 2026-02-10, reports 11.7%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 20 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for LB Pharmaceuticals Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for LB Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.

• Get an alert when LB Pharmaceuticals Inc is mentioned again
• Find former LB Pharmaceuticals Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes